A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Pilot Study for the Use of Shortened Preemptive Therapy With Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney, Heart, Lung and/or Pancreas) of Hepatitis C Viremic Donors

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

Inclusion criteria:

• Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection
• Willing to accept and consent for accepting hepatitis C positive graft

Exclusion criteria:

• Existing chronic liver disease (liver cirrhosis)
• Concomitant infection with HIV or Chronic hepatitis B
• Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection
• Pregnancy (Pregnant patients do not undergo solid organ transplants)